EZR and metastatic malignant neoplasm in the lymph nodes: Moreover, miR-183 has been considered a metastatic inhibitor by targeting ezrin[53] and lymph node metastasis in medullary thyroid carcinoma[54], and this miRNA was recently described as being involved in breast cancer progression[55].